In fiscal 2024, which ended Jun 30, 2024, Renalytix plc reported revenue of $2.3 million, down 32.7% from the year before. It recorded a net loss of $33.5 million. The operating loss came to $29.6 million, an operating margin of -1293.5%. Diluted earnings per share were -$0.31. Over the twelve months ended Sep 30, 2024, revenue was $2.4 million and the net loss was $28.0 million. Across the 4 fiscal years shown, revenue grew from $1.5 million in fiscal 2021 to $2.3 million in fiscal 2024, about 15.4% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2024
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
|---|---|---|---|---|---|---|
| Revenue |
2
|
2
-32.7%
|
3
+14.6%
|
3
+99.2%
|
1
|
—
|
| Cost of revenue |
2
|
2
-20.5%
|
3
+28.0%
|
2
+144.3%
|
1
|
—
|
| Gross profit |
0
|
0
-78.3%
|
1
-17.6%
|
1
+38.1%
|
1
|
—
|
| Selling, general and administrative |
17
|
20
-31.1%
|
29
-27.5%
|
40
+68.3%
|
23
+308.3%
|
6
|
| Operating income |
-25
|
-30
+29.9%
|
-42
+20.6%
|
-53
-66.6%
|
-32
-209.4%
|
-10
|
| Pretax income |
-28
|
-33
+26.6%
|
-46
-0.8%
|
-45
-28.1%
|
-35
-259.0%
|
-10
|
| Income tax |
0
|
0
+100.0%
|
0
-92.0%
|
0
|
—
|
—
|
| Net income |
-28
|
-33
+26.6%
|
-46
-0.7%
|
-45
-28.1%
|
-35
-259.0%
|
-10
|
| Basic EPS |
-0.25
|
-0.31
+43.6%
|
-0.55
+11.3%
|
-0.62
|
—
|
—
|
| Diluted EPS |
-0.25
|
-0.31
+43.6%
|
-0.55
+17.9%
|
-0.67
|
—
|
—
|
| Weighted average shares, basic |
111
|
108
+31.6%
|
82
+12.8%
|
73
|
—
|
—
|
| Weighted average shares, diluted |
111
|
108
+31.6%
|
82
+11.3%
|
74
|
—
|
—
|
| Other measures | ||||||
| Depreciation and amortization |
0
|
0
-28.3%
|
1
+3.9%
|
0
+73.4%
|
0
+302.9%
|
0
|
| EBITDA |
-25
|
-29
+29.9%
|
-42
+20.8%
|
-53
-66.6%
|
-32
-208.8%
|
-10
|
| Margins | ||||||
| Gross margin |
12.71%
|
6.82%
|
21.16%
|
29.43%
|
42.45%
|
—
|
| Operating margin |
-1,054.93%
|
-1,293.49%
|
-1,240.70%
|
-1,790.67%
|
-2,140.58%
|
—
|
| Pretax margin |
-1,191.50%
|
-1,461.42%
|
-1,340.14%
|
-1,523.60%
|
-2,369.95%
|
—
|
| Profit margin |
-1,191.75%
|
-1,461.60%
|
-1,340.20%
|
-1,524.44%
|
-2,369.95%
|
—
|
| EBITDA margin |
-1,042.30%
|
-1,277.59%
|
-1,225.77%
|
-1,774.21%
|
-2,121.66%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.